Pharma ADMET Testing Global Market Report 2024

Pharmaceutical ADMET testing encompasses a series of methodologies and assays employed in the pharmaceutical sector to evaluate the Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) characteristics of drug candidates. This essential process is instrumental in gauging the safety and effectiveness of prospective drugs prior to obtaining regulatory approval for clinical application.

The primary categories of pharma ADMET testing include in vivo ADMET testing, in vitro ADMET testing, and in silico ADMET testing. In vivo ADMET testing involves the analysis of a drug's absorption, distribution, metabolism, excretion, and toxicity attributes within a living organism. Widely utilized throughout drug discovery and development phases, pharma ADMET testing plays a crucial role in pinpointing potential drug candidates endowed with favorable pharmacokinetic properties. Utilizing advanced technologies such as cell culture, high throughput, molecular imaging, and OMICS, pharma ADMET testing is pivotal in assessing systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and other relevant parameters. This comprehensive approach aids in the strategic identification of drug candidates that align with desired efficacy and safety profiles, thereby contributing to informed decision-making in the pharmaceutical business landscape.

The pharma ADMET testing market research report is one of a series of new reports from The Business Research Company that provides pharma ADMET testing market statistics, including the pharma ADMET testing industry's global market size, regional shares, competitors with a pharma ADMET testing market share, detailed pharma ADMET testing market segments, market trends, and opportunities, and any further data you may need to thrive in the pharma ADMET testing industry. This pharma ADMET testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pharma admet testing market size has grown rapidly in recent years. It will grow from $8.62 billion in 2023 to $9.61 billion in 2024 at a compound annual growth rate (CAGR) of 11.5%.The expansion observed in the historical period can be ascribed to the increasing prominence of biopharmaceuticals and biosimilars, a surge in drug development initiatives, heightened awareness concerning drug safety, the globalization of clinical trials, and a notable shift towards in silico modeling.

The pharma admet testing market size is expected to see rapid growth in the next few years. It will grow to $14.87 billion in 2028 at a compound annual growth rate (CAGR) of 11.5%. The anticipated expansion in the forecast period can be credited to factors such as increased emphasis on environmental toxicology and safety assessment, heightened awareness of pharmacogenomics, a strategic focus on precision medicine, the growing prevalence of biologics and biosimilars, the integration of artificial intelligence (AI), heightened regulatory requirements, and an upswing in orphan drug development. Notable trends expected in the forecast period encompass a rise in collaborative research efforts, rapid technological innovations, advancements in analytical technologies, ongoing vigilance in drug safety monitoring, and a heightened consideration of environmental impacts.

The upward trend in product approvals is a key driver for the pharma ADMET testing market. Product approvals involve the regulatory endorsement by authorities such as the Food and Drug Administration (FDA) in the United States or the European Medicines Agency (EMA) in Europe, allowing products to be marketed to the public. ADMET testing plays a crucial role in assessing the safety and efficacy of new products, and its inclusion is mandatory in the regulatory approval process. Notably, the Center for Drug Evaluation and Research reported that in 2020, 53 drugs received approval in the United States, indicating an increase from the 48 drugs approved in 2019. Consequently, the growing number of product approvals serves as a catalyst for the pharma ADMET testing market.

The surge in clinical trials is expected to drive the pharma ADMET testing market's growth in the future. Clinical trials, essential research studies involving human participants, evaluate the safety, efficacy, and potential side effects of medical interventions, including new drugs, medical devices, diagnostic procedures, or treatment regimens. The escalating number of clinical trials significantly amplifies the demand for comprehensive assessments of drug safety and efficacy within the pharma ADMET testing market. For example, a report from Xtalks reveals that, as of May 2023, there are 452,604 registered clinical studies on ClinicalTrials.gov, indicating a notable increase from the over 365,000 trials recorded in early 2021. This uptick underscores the industry's growing need for tailored evaluations across diverse drug candidates and patient populations, thereby propelling the pharma ADMET testing market's expansion.

A prominent trend gaining traction in the pharma ADMET testing market is the focus on product innovations, with major companies introducing cutting-edge solutions to enhance their market position. Notably, Charles River Laboratories International Inc. and Valo Health Inc. launched Logica in April 2022-an AI-based drug development solution. Leveraging Valo's Opal Computational Platform, Logica provides users with ADMET testing services and other drug delivery solutions. The solution incorporates industry-leading predictive models, chemical design and synthesis capabilities, DNA-encoded libraries, and in silico high-throughput screening. Charles River's expertise in various discovery optimization aspects, including high-throughput screening, medicinal chemistry, ADME, biology, pharmacology, safety testing, and IND submission, further enhances Logica's capabilities.

Major players in the pharma ADMET testing market are strategically engaging in partnerships to advance efforts in discovering allosteric drugs. An illustrative example is the collaboration between Excelra and HotSpot Therapeutics Inc. In May 2022, Excelra, specializing in accelerating drug discovery through advanced data science, partnered with HotSpot Therapeutics Inc., a biotechnology company focused on small molecule allosteric therapies. This strategic alliance involves integrating Excelra's product, GOSTAR, and its annotated datasets into HotSpot's machine learning (ML) and artificial intelligence (AI) models. GOSTAR, with insights into over 8 million small molecules, provides comprehensive information on chemical structures and various biological properties, facilitating the exploration and development of small molecule therapeutic candidates targeting challenging allosteric sites.

In September 2022, BioIVT, a prominent drug development solutions provider based in the United States, successfully completed the acquisition of XenoTech for an undisclosed sum. This strategic move is designed to enhance BioIVT's product portfolio by integrating XenoTech's capabilities and to facilitate the expansion of its product offerings into new geographic regions, thereby reaching a broader customer base. XenoTech, a respected US-based contract research organization, specializes in offering ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) testing services. This acquisition underscores BioIVT's commitment to strengthening its position in the drug development sector by incorporating complementary expertise and extending its reach to cater to evolving market demands.

Major companies operating in the pharma admet testing market report are Thermo Fisher Scientific Inc., Abbott Laboratories, The Merck Group, Laboratory Corporation of America Holdings, IQVIA Inc., PPD ICON PLC, Agilent Technologies Inc., Wuxi AppTec Co. Ltd., Catalent Inc., Covance Inc., Charles River Laboratories International Inc., Eurofins Scientific SE, Beckman Coulter Inc., Perkinelmer Inc., Bio-Rad Laboratories Inc., Albany Molecular Research Inc., Evotec A.G., CMIC Holdings Co. Ltd., Promega Corporation, Aptuit LLC, Symeres B.V., Biovia Corp., BioIVT LLC, Cyprotex Limited, InSphero AG, Admescope Ltd., Accelrys Inc.

Asia-Pacific was the largest region in the pharma ADMET testing market in 2023. The regions covered in the pharma admet testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the pharma admet testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pharma ADMET testing market consists of revenues earned by entities by providing services such as in vitro screening, in vitro metabolism, and metabolite testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharma ADMET testing market also includes the sales of membranes, buffer systems, and analytes that are used in the assays. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pharma ADMET Testing Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pharma admet testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pharma admet testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pharma admet testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Testing Type: In Vivo ADMET Testing; In Vitro ADMET Testing; In Silico ADMET Testing
• 2) By Technology: Cell Culture; High Throughput; Molecular Imaging; OMICS Technology
• 3) By Application: Systemic Toxicity; Renal Toxicity; Hepatotoxicity; Neurotoxicity; Other Applications
• Companies Mentioned: Thermo Fisher Scientific Inc.; Abbott Laboratories; The Merck Group; Laboratory Corporation of America Holdings; IQVIA Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.